Next 10 |
2024-05-13 19:31:09 ET Allogene Therapeutics, Inc. (ALLO) Q1 2024 Earnings Conference Call May 13, 2024, 05:00 PM ET Company Participants Christine Cassiano - Chief Corporate Affairs & Brand Strategy Officer David Chang - President & Chief Executive Officer ...
2024-05-13 17:06:07 ET Gainers: Harrow ( HROW ) +15% . Fulcrum Therapeutics ( FULC ) +7% . Allogene Therapeutics ( ALLO ) +6% . Infinera Corporation ( INFN ) +6% . Voyager Therapeutics ( VYGR ) +5% . Losers: Akoya BioScie...
2024-05-13 16:59:14 ET More on Allogene Therapeutics Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside Allogene Therapeutics, Inc. (ALLO) Q4 2023 Earnings Call Transcript Allogene Therapeutics Q1 2024 Earnings Preview Allogene Therapeutics GAA...
SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the pricing of an underwr...
2024-05-13 16:09:59 ET More on Allogene Therapeutics Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside Allogene Therapeutics, Inc. (ALLO) Q4 2023 Earnings Call Transcript Allogene Therapeutics Q1 2024 Earnings Preview Allogene Therapeutics GAA...
Cemacabtagene Ansegedleucel (Cema-Cel) Expanded CD19 Oncology Rights to Include all EU Member States and the United Kingdom, Reinforcing Company’s Conviction in the Unique Opportunity in Large B Cell Lymphoma (LBCL) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) ...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...
2024-05-12 17:35:55 ET Major earnings expected after the bell on Monday include: Petróleo Brasileiro S.A. - Petrobras ( PBR ) Lithium Americas (Argentina) Corp. ( LAC ) StoneCo Ltd. ( STNE ) Inovio Pharmaceuticals ( INO ) Alcon ( ALC ) ...
2024-05-12 17:35:00 ET More on Allogene Therapeutics Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside Allogene Therapeutics, Inc. (ALLO) Q4 2023 Earnings Call Transcript Allogene Therapeutics GAAP EPS of -$0.51 misses by $0.06 Allogene Therap...
2024-05-12 11:22:00 ET This week, the healthcare sector saw 12 companies reporting their quarterly earnings, with 8 of them beating their bottom-line numbers for the quarter.... Read the full article on Seeking Alpha For further details see: 8 out of 12 S&P 500 healthcar...
News, Short Squeeze, Breakout and More Instantly...
Allogene Therapeutics Inc. Company Name:
ALLO Stock Symbol:
NASDAQ Market:
Allogene Therapeutics Inc. Website:
Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) rose sharply in today's pre-market trading after the company reported better-than-expect...
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 20 points on Wednesday. Shares of DLocal Limited (NASDAQ:...
SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the pricing of an underwr...